Harbinger Health, a company focused on early cancer detection, has secured a significant funding of $140 million in a series B financing round. The company is developing a range of liquid biopsy tests and a software program to analyze blood samples for early signs of cancer. The funding was led by Flagship Pioneering, which had previously brought Harbinger out of stealth in 2021, and saw participation from new investors including Pictet, Partners Investment, and M&G Investments’ Catalyst fund.
- Harbinger’s total funding now stands close to $200 million since its inception. The series B funds will be used to further develop its testing model, machine learning software, and to fund an ongoing study with 10,000 participants to validate the cancer screening platform.
- The company aims to launch its first product by 2025, which will be a laboratory-developed blood test. This test will utilize the HarbingerHx software to identify biological abnormalities indicative of early cancer development.
- A study presented at the American Society of Clinical Oncology’s annual meeting revealed that Harbinger’s machine learning algorithm could detect cancer with 82% sensitivity and 95% specificity. The sensitivity increased with the progression of cancer.